FHC Focus Morningstar Health Care Index Etf

CHICAGO, Sept. 29 /PRNewswire-FirstCall/ -- The Female Health Company (AMEX:FHC) announced that it has received an order from John Snow, Inc., which implements the USAID | DELIVER PROJECT, for the delivery of up to 10 million female condoms (FC) for the United States Agency for International Development (USAID) supported programs. Under its original order, placed in February 2008, FHC has delivered approximately 6.1 million units. FHC has been requested to deliver the balance of the order, up to 3.9 million units, by December 31, 2008 to satisfy increased demand for the female condom. For many years, USAID has been among the largest international donors of contraceptives and condoms. The Agency developed an operational plan for its HIV/AIDS "expanded response" strategy which includes the establishment of the Commodity Fund (CF) to centrally-finance male and female condoms for HIV/AIDS programs and to ensure their expedited delivery to countries. Through the Commodity Fund, which began in 2002, USAID provides male and female condoms to Missions for HIV/AIDS prevention activities. However, under the President's Emergency Plan for AIDS Relief (PEPFAR), focus countries are required to include male and female condoms for their HIV/AIDS programs as an activity/budget line item in their country operational plans. Focus countries need to budget and pay for the male and female condoms they need, and will not be eligible to obtain condoms free of charge from the CF. Non-focus countries will continue to be able to request condoms for free from the CF. O. B. Parrish, Chairman and CEO of FHC, praised USAID actions stating, "In continuing female condom procurement in 2008, USAID is demonstrating its commitment to supporting HIV/AIDS prevention efforts around the World. This commitment is particularly critical as the Global Community recognizes the increasing numbers of females affected by AIDS." UNAIDS reports that worldwide, 33.2 million people--15.4 million of which are women aged 15 years and older are now living with HIV. The Global Coalition on Women and AIDS, a UNAIDS Initiative, is calling for more money in AIDS programs that work for women including closing the funding gap for the female condom and microbicides development." About The Female Health Company, Inc. The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R), which is primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. World-wide, the Female Condom is available in various programs in 108 countries. The Company owns certain worldwide rights to the FC Female Condom(R), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC Female Condom(R) is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. For more information about the Female Health Company, visit the Company's web site at http://www.femalehealth.com/ or http://www.femalecondom.org/. "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release may be identified by the use of forward-looking words or phrases such as "anticipate,' "believe,' "could,' "expect,' "intend,' "may,' "planned,' "potential,' "should,' "will,' "would' or the negative of those terms or other words of similar meaning. These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings, including the Company's Form 10-KSB for the fiscal year ended September 30, 2007. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated. DATASOURCE: The Female Health Company, Inc. CONTACT: investors, William R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch, +1-312-595-9742, both of The Female Health Company, Inc. Web Site: http://www.femalecondom.org/ http://www.femalehealth.com/

Copyright